Zhaoke (Guangzhou) Pharmaceutical Limited   Report issue

Government Phase 1 Phase 3 Phase 4
Founded: Guangzhou China (1951)

Organization Overview

First Clinical Trial
2017
NCT03270735
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Limited | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Zhaoke (Guangzhou) Pharmaceutical Limited | Zhaoke Pharmaceutical (Hefei) Company Limited

Active Ingredients

Drugs in Phase 4 Trials (1)

snake venom thrombin (1 trial)

Drugs in Phase 3 Trials (6)

adapalene (differin) (1 trial)

clindamycin (cleocin) (1 trial)

cyclosporine (sandimmune) (1 trial)

hypromelloses (1 trial)

ranibizumab (lucentis) (1 trial)

tab014 (1 trial)

Drugs in Phase 1 Trials (1)

azilsartan (edarbi) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Vulgaris (Phase 3)

Dry Eye Syndromes (Phase 3)

Eye Diseases (Phase 3)

Hemoptysis (Phase 4)

Keratoconjunctivitis Sicca (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 8